DRPSHP

Scientific Reference

Survodutide

Evidence profile: Human Phase 3 evidence

Survodutide (development code BI 456906) belongs to a design family that pairs glucagon receptor activation with GLP-1 receptor activation in one molecule; related triple agonists add the GIP receptor to the mix. It is a lipidated peptide, meaning a fatty-acid chain has been attached to extend its time in circulation, a device shared by other long-acting peptides of this type. Its record spans receptor assays, rodent work and human trials aimed at metabolic and liver conditions. Relative to older incretin compounds the peer-reviewed literature is brief and recent, so conclusions remain provisional.

Mechanism of Action

Both targets are class B G protein-coupled receptors acting mainly via Gs and cyclic AMP. Glucagon receptors are concentrated in the liver, where signalling has been examined for effects on glucose production, amino-acid handling and fatty-acid oxidation. GLP-1 receptors occur in pancreatic islets and in brain areas implicated in feeding. Rodent experiments with dual agonists have followed hepatic fat and energy expenditure. Researchers are still working out how much each receptor contributes to the activity observed in living animals.

Molecular Information

  • Type: Lipidated dual-agonist peptide
  • Molecular weight: 4232 g/mol
  • Molecular formula: C192H289N47O61

Published Research

  • SYNCHRONIZE-1

    Survodutide Once Weekly for the Treatment of Adults with Obesity

    le Roux CW et al. · The New England journal of medicine · 2026 · Clinical

    PMID 42253238 — View on PubMed

  • SYNCHRONIZE-MASLD

    Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

    Kaplan LM et al. · Nature medicine · 2026 · Clinical

    PMID 42252333 — View on PubMed

  • A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

    Sanyal AJ et al. · The New England journal of medicine · 2024 · Clinical

    PMID 38847460 — View on PubMed

  • Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

    le Roux CW et al. · The lancet. Diabetes & endocrinology · 2024 · Clinical

    PMID 38330987 — View on PubMed

  • Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes

    Wharton S et al. · Diabetes, obesity & metabolism · 2026 · Clinical

    PMID 41216778 — View on PubMed

  • Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

    Blüher M et al. · Diabetologia · 2024 · Clinical

    PMID 38095657 — View on PubMed